Nissay Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$5.31M Buy
16,288
+74
+0.5% +$24.1K 0.03% 314
2025
Q1
$4.38M Buy
16,214
+267
+2% +$72.1K 0.03% 336
2024
Q4
$3.79M Buy
15,947
+324
+2% +$77.1K 0.02% 372
2024
Q3
$4.3M Sell
15,623
-478
-3% -$131K 0.03% 349
2024
Q2
$3.91M Buy
16,101
+524
+3% +$127K 0.03% 348
2024
Q1
$2.33M Buy
15,577
+319
+2% +$47.7K 0.02% 459
2023
Q4
$2.92M Buy
15,258
+485
+3% +$92.8K 0.02% 371
2023
Q3
$2.62M Buy
14,773
+537
+4% +$95.1K 0.02% 376
2023
Q2
$2.7M Sell
14,236
-280
-2% -$53.2K 0.02% 379
2023
Q1
$2.91M Sell
14,516
-194
-1% -$38.9K 0.03% 351
2022
Q4
$3.5M Sell
14,710
-48
-0.3% -$11.4K 0.03% 301
2022
Q3
$2.95M Buy
14,758
+556
+4% +$111K 0.03% 321
2022
Q2
$2.07M Buy
14,202
+179
+1% +$26.1K 0.02% 399
2022
Q1
$2.29M Buy
14,023
+386
+3% +$63K 0.02% 432
2021
Q4
$2.31M Buy
13,637
+371
+3% +$62.9K 0.02% 447
2021
Q3
$2.51M Buy
13,266
+1,913
+17% +$361K 0.02% 403
2021
Q2
$1.93M Buy
11,353
+270
+2% +$45.8K 0.02% 457
2021
Q1
$1.57M Sell
11,083
-289
-3% -$40.8K 0.02% 492
2020
Q4
$1.48M Sell
11,372
-168
-1% -$21.8K 0.02% 491
2020
Q3
$1.68M Buy
11,540
+474
+4% +$69K 0.03% 398
2020
Q2
$1.64M Buy
11,066
+1,455
+15% +$216K 0.03% 411
2020
Q1
$1.05M Buy
9,611
+400
+4% +$43.5K 0.03% 438
2019
Q4
$1.06M Sell
9,211
-82
-0.9% -$9.45K 0.02% 508
2019
Q3
$747K Buy
9,293
+1,498
+19% +$120K 0.02% 570
2019
Q2
$566K Buy
7,795
+233
+3% +$16.9K 0.01% 634
2019
Q1
$707K Buy
7,562
+394
+5% +$36.8K 0.02% 578
2018
Q4
$523K Buy
7,168
+507
+8% +$37K 0.02% 595
2018
Q3
$583K Buy
6,661
+259
+4% +$22.7K 0.02% 613
2018
Q2
$631K Sell
6,402
-5,075
-44% -$500K 0.02% 584
2018
Q1
$1.37M Buy
11,477
+160
+1% +$19.1K 0.04% 358
2017
Q4
$1.44M Buy
+11,317
New +$1.44M 0.04% 350